Worth separating two things that post #3 runs together.
Biased agonism — where different ligands at the same receptor favour different downstream pathways — is a plausible explanation for differences between compounds in this class and is not a demonstrated one for any specific pair.
Useful. I had the fact and not the reason, which turns out to be the important half.
I had written a reply contradicting post #23 and deleted it. Here is what survived.
Ghrelin receptor agonism drives growth hormone release in pulses and also increases appetite, which is the effect people most reliably report and least often want.
Post #27 answers the question as asked. The question underneath it is different.
Biased agonism: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
Coming back to post #32, because the follow-up matters more than the original answer.
Biased agonism — where different ligands at the same receptor favour different downstream pathways — is a plausible explanation for differences between compounds in this class and is not a demonstrated one for any specific pair.
I have no interest in any supplier named above.
The useful distinction on Biased agonism is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
Fine by me. I had wanted a stronger conclusion and there is not one available.
Read the full topic (57 posts)
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Appetite effects: what I expected, what I found, and the gap between them. I…
|
2 | 56k | 16mo | |
|
Follow-up: Why appetite effects are mostly central
Asking directly, because I could not find a straight answer: Why appetite effects are mostly central A follow-up question about appetite effects that I did not know to ask the first time. The earlier thread…
|
+86 | 90 | 61k | 9mo |
|
Vagal afferents and the gut-brain pathway
On the subject in the title: Vagal afferents and the gut-brain pathway Working notes rather than a conclusion. Vagal afferents — I have the observation and I do not trust my interpretation of it, so I am…
|
+5 | 9 | 44k | 13mo |
|
GIP receptor agonism and the argument about direction
GIP receptor agonism and the argument about direction — setting out what I have, and where I think it stops being reliable. A question about GIP receptor agonism that I think has a definite answer, unlike…
|
2 | 867 | 10mo | |
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. What changes if the standard account of Amylin receptor signalling and satiety…
|
+73 | 78 | 3.5k | 2mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
|
+3 | 7 | 1k | 2mo |
|
Follow-up: The lowest dose that does anything: is that a real question?
The question in the title: The lowest dose that does anything: is that a real question? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still…
|
+70 | 75 | 12k | 8mo |
|
Spreadsheets: an appreciation
On the subject in the title: Spreadsheets: an appreciation Working notes rather than a conclusion. A methods question rather than a substantive one, about spreadsheets. Everyone quotes the same figure and I…
|
+26 | 30 | 25k | 2.1y |
|
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of clearance pathways is wrong? I…
|
+11 | 15 | 43k | 2mo |
|
Peak-to-trough ratio at steady state for a weekly agent
On the subject in the title: Peak-to-trough ratio at steady state for a weekly agent Working notes rather than a conclusion. Working through the kinetics rather than the pharmacology, because I think the…
|
+58 | 64 | 9.7k | 2mo |